Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Key Laboratory of Urology, Guangzhou, Guangdong, China.
Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Clin Chim Acta. 2018 Aug;483:64-68. doi: 10.1016/j.cca.2018.04.024. Epub 2018 Apr 17.
The prognostic value of homeobox (HOX) A13 (HOXA13) in cancer remains uncertain due to limitations of sample size and discrete outcome in previous studies. We performed this meta-analysis to explore the prognostic effect of HOXA13 in patients with solid tumors.
PubMed, Embase, and Web of Science were searched to identify eligible studies. Hazard ratios (HR) with 95% confidence interval (95%CI) and clinicopathological factors were extracted. Subgroup analysis according to cancer type, sample size and analysis method were also performed.
A total of 844 patients with solid tumor from 9 eligible studies were incorporated in the meta-analysis. We found that high HOXA13 expression level was significantly associated with poor overall survival (OS) in human cancer (HR = 2.23; 95%CI: 1.74-2.85), and significantly related to poorer histological grade (odds ratio (OR) = 2.03, 95%CI: 1.40-2.96), positive lymph node metastasis (OR = 1.96, 95%CI: 1.26-3.02) and more advanced tumor-node-metastasis (TNM) stage (OR = 3.92, 95%CI: 2.46-6.22).
Our meta-analysis suggests that HOXA13 might be a valuable biomarker of poor prognosis and a potential therapeutic target for human solid tumors.
由于既往研究中样本量有限且结局离散，HOX 基因家族成员 A13（HOXA13）在癌症中的预后价值仍不确定。我们进行了这项荟萃分析，以探讨 HOXA13 对实体瘤患者的预后影响。
检索 PubMed、Embase 和 Web of Science 以确定合格的研究。提取危险比（HR）及其 95%置信区间（95%CI）和临床病理因素。还根据癌症类型、样本量和分析方法进行了亚组分析。
共有 9 项合格研究的 844 名实体瘤患者纳入荟萃分析。我们发现，HOXA13 高表达水平与人类癌症的总生存期（OS）不良显著相关（HR=2.23；95%CI：1.74-2.85），且与组织学分级较差（OR=2.03，95%CI：1.40-2.96）、阳性淋巴结转移（OR=1.96，95%CI：1.26-3.02）和更晚期的肿瘤-淋巴结-转移（TNM）分期（OR=3.92，95%CI：2.46-6.22）显著相关。
我们的荟萃分析表明，HOXA13 可能是预后不良的有价值的生物标志物，也是人类实体瘤潜在的治疗靶点。
